Washington Report

Apr 01, 2012
Pharmaceutical Executive
Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors.
Mar 01, 2012
Pharmaceutical Executive
FDA and industry are pushing user fees, while they struggle with curbs on communications.
Feb 01, 2012
Pharmaceutical Executive
Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices?
Jan 01, 2012
Pharmaceutical Executive
Look for action in 2012 on drug access, shortages, innovation, and transparency.
Dec 01, 2011
Pharmaceutical Executive
Agency expansion and globalization promote innovation, collaboration, and organizational changes
Nov 01, 2011
Pharmaceutical Executive
Clamor for critical therapies prompts probes of prices, production practices.
Sep 01, 2011
Pharmaceutical Executive
User-fee renewal legislation sets the stage for new policies affecting reimbursement, research, and regulatory oversight.
Aug 01, 2011
Pharmaceutical Executive
A number of important decisions from the Supreme Court will affect drug marketing, research, and regulation
Jul 01, 2011
Pharmaceutical Executive
Sponsors must handle interchangeability, exclusivity, cost and coverage hurdles to win biosimilars game
Jun 01, 2011
Pharmaceutical Executive
FDA's opiod REMS implies there is still value in industry-sponsored CME
native1_300x100
lorem ipsum